Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Policy / Regulatory

NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions

Fineline Cube Jan 23, 2024

The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...

Company Deals

Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine

Fineline Cube Jan 23, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...

Company Deals

Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements

Fineline Cube Jan 23, 2024

Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...

Company Deals

Digital Precision Medicine Secures Over $28 Million in Series C Financing

Fineline Cube Jan 22, 2024

Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...

Company Drug

NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin

Fineline Cube Jan 22, 2024

The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...

Company Drug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

Fineline Cube Jan 22, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...

Company Drug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

Fineline Cube Jan 22, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...

Company Drug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

Fineline Cube Jan 22, 2024

The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...

Policy / Regulatory

Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth

Fineline Cube Jan 22, 2024

Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...

Company

Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches

Fineline Cube Jan 22, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...

Company Drug

Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis

Fineline Cube Jan 22, 2024

Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...

Company Deals

Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines

Fineline Cube Jan 22, 2024

Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured...

Company Deals R&D

Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI

Fineline Cube Jan 22, 2024

Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent

Fineline Cube Jan 22, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...

Company

HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province

Fineline Cube Jan 22, 2024

HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made...

Company Deals Digital R&D

AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics

Fineline Cube Jan 22, 2024

Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...

Company Drug

InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA

Fineline Cube Jan 22, 2024

InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...

Policy / Regulatory

Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development

Fineline Cube Jan 22, 2024

The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...

Company Deals

Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China

Fineline Cube Jan 19, 2024

Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...

Company Drug

BeiGene Submits Additional Application for Tislelizumab in NSCLC in China

Fineline Cube Jan 19, 2024

BeiGene (NASDAQ: BGNE) has announced the submission of a supplementary Biologic License Application in China...

Posts pagination

1 … 368 369 370 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.